Progression-free survival as surrogate endpoint in advanced pancreatic cancer: Meta-analysis of 30 randomized first-line trials

Hepatobiliary and Pancreatic Diseases International

Volumn 14, Issue 2, 2015, Pages 124-131

  Petrelli, Fausto ^a   Coinu, Andrea ^a   Borgonovo, Karen ^a   Cabiddu, Mary ^a   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

correlation; overall survival; pancreatic cancer; progression free survival; randomized studies; surrogate endpoints

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PEMETREXED; UFT; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DEOXYCYTIDINE;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COCHRANE LIBRARY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; WEB OF SCIENCE; ANALOGS AND DERIVATIVES; CARCINOMA, PANCREATIC DUCTAL; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; PANCREATIC NEOPLASMS; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL;

EID: 84941894146     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(15)60344-7     Document Type: Article

References (53)

1. H Ueno, T Ioka, M Ikeda, S Ohkawa, H Yanagimoto, N Boku et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study J Clin Oncol 31 2013 1640 1648
2. T Conroy, F Desseigne, M Ychou, O Bouché, R Guimbaud, Y Bécouarn et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
3. M Buyse, T Burzykowski, K Carroll, S Michiels, DJ Sargent, LL Miller et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer J Clin Oncol 25 2007 5218 5224
4. X Paoletti, K Oba, YJ Bang, H Bleiberg, N Boku, O Bouché et al. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis J Natl Cancer Inst 105 2013 1667 1670
5. F Petrelli, S Barni Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer Ann Oncol 24 2013 186 192
6. KR Broglio, DA Berry Detecting an overall survival benefit that is derived from progression-free survival J Natl Cancer Inst 101 2009 1642 1649
7. K Hotta, K Kiura, Y Fujiwara, N Takigawa, A Hisamoto, E Ichihara et al. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review PLoS One 6 2011 e26646
8. ED Saad, A Katz Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined Ann Oncol 20 2009 460 464
9. C Giessen, RP Laubender, DP Ankerst, S Stintzing, DP Modest, U Mansmann et al. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials Clin Cancer Res 19 2013 225 235
10. U Pelzer, I Schwaner, J Stieler, M Adler, J Seraphin, B Dörken et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group Eur J Cancer 47 2011 1676 1681
11. D Moher, A Liberati, J Tetzlaff, DG Altman, PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 6 2009 e1000097
12. PA Tang, SM Bentzen, EX Chen, LL Siu Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy J Clin Oncol 25 2007 4562 4568
13. C Chirila, D Odom, G Devercelli, S Khan, BN Sherif, JA Kaye et al. Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer Int J Colorectal Dis 27 2012 623 634
14. F Petrelli, S Barni Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials Med Oncol 31 2014 776
15. JM Bland, DG Altman Calculating correlation coefficients with repeated observations: Part 2-Correlation between subjects BMJ 310 1995 633
16. JM Bland, DG Altman Calculating correlation coefficients with repeated observations: Part 1-Correlation within subjects BMJ 310 1995 446
17. DD Von Hoff, T Ervin, FP Arena, EG Chiorean, J Infante, M Moore et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 2013 1691 1703
18. H Riess, A Helm, M Niedergethmann, I Schmidt-Wolf, M Moik, C Hammer et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer J Clin Oncol 23 2005 LBA4009
19. S Ohkawa Randomized controlled trial of gemcitabine in combination with UFT versus gemcitabine alone in patients with advanced pancreatic cancer J Clin Oncol 22 2004 4131
20. CP Li, Y Chao A prospective randomized trial of gemcitabine alone or gemcitabine+cisplatin in the treatment of metastatic pancreatic cancer J Clin Oncol 22 2004 4144
21. F Viret, M Ychou, D Lepille, L Mineur, F Navarro, D Topart et al. Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: final results of a multicenter randomized phase II study J Clin Oncol 22 2004 4118
22. X Wang, Q Ni, M Jin, Z Li, Y Wu, Y Zhao et al. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer Zhonghua Zhong Liu Za Zhi 24 2002 404 407
23. JD Berlin, P Catalano, JP Thomas, JW Kugler, DG Haller, AB Benson 3rd Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 2002 3270 3275
24. G Colucci, F Giuliani, V Gebbia, M Biglietto, P Rabitti, G Uomo et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale Cancer 94 2002 902 910
25. W Scheithauer, B Schüll, H Ulrich-Pur, K Schmid, M Raderer, K Haider et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial Ann Oncol 14 2003 97 104
26. CM Rocha Lima, MR Green, R Rotche, WH Miller Jr, GM Jeffrey, LA Cisar et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 2004 3776 3783
27. C Louvet, R Labianca, P Hammel, G Lledo, MG Zampino, T André et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 2005 3509 3516
28. M Reni, S Cordio, C Milandri, P Passoni, E Bonetto, C Oliani et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial Lancet Oncol 6 2005 369 376
29. F Di Costanzo, P Carlini, L Doni, B Massidda, R Mattioli, A Iop et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC) Br J Cancer 93 2005 185 189
30. H Oettle, D Richards, RK Ramanathan, JL van Laethem, M Peeters, M Fuchs et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer Ann Oncol 16 2005 1639 1645
31. V Heinemann, D Quietzsch, F Gieseler, M Gonnermann, H Schönekäs, A Rost et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J Clin Oncol 24 2006 3946 3952
32. GP Stathopoulos, K Syrigos, G Aravantinos, A Polyzos, P Papakotoulas, G Fountzilas et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer Br J Cancer 95 2006 587 592
33. E Poplin, Y Feng, J Berlin, ML Rothenberg, H Hochster, E Mitchell et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group J Clin Oncol 27 2009 3778 3785
34. R Herrmann, G Bodoky, T Ruhstaller, B Glimelius, E Bajetta, J Schüller et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group J Clin Oncol 25 2007 2212 2217
35. D Cunningham, I Chau, DD Stocken, JW Valle, D Smith, W Steward et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27 2009 5513 5518
36. G Colucci, R Labianca, F Di Costanzo, V Gebbia, G Cartenì, B Massidda et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study J Clin Oncol 28 2010 1645 1651
37. MH Kulke, MA Tempero, D Niedzwiecki, DR Hollis, HL Kindler, M Cusnir et al. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904 J Clin Oncol 27 2009 5506 5512
38. L Dahan, F Bonnetain, M Ychou, E Mitry, M Gasmi, JL Raoul et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301) Gut 59 2010 1527 1534
39. Y Nakai, H Isayama, T Sasaki, N Sasahira, T Tsujino, N Toda et al. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study Br J Cancer 106 2012 1934 1939
40. M Ozaka, Y Matsumura, H Ishii, Y Omuro, T Itoi, H Mouri et al. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study) Cancer Chemother Pharmacol 69 2012 1197 1204
41. I Trouilloud, AC Dupont-Gossard, P Artru, T Lecomte, M Gauthier, T Aparicio et al. FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): Results of the randomized multicenter AGEO phase II trial FIRGEM J Clin Oncol 30 2012 4018
42. GK Abou-Alfa, R Letourneau, G Harker, M Modiano, H Hurwitz, NS Tchekmedyian et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer J Clin Oncol 24 2006 4441 4447
43. JM Löhr, SL Haas, WO Bechstein, G Bodoky, K Cwiertka, W Fischbach et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial Ann Oncol 23 2012 1214 1222
44. Y Chao, CY Wu, JP Wang, RC Lee, WP Lee, CP Li A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer Cancer Chemother Pharmacol 72 2013 637 642
45. OE Rahma, A Duffy, DJ Liewehr, SM Steinberg, TF Greten Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials Ann Oncol 24 2013 1972 1979
46. MY Teo, RS McDermott Activity and survival benefit of second-line chemotherapy (2L-Ctx) in advanced pancreatic adenocarcinoma (APC): pooled analysis of the literature J Clin Oncol 31 2013 e15019
47. H Oettle, H Riess, JM Stieler, G Heil, I Schwaner, J Seraphin et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial J Clin Oncol 32 2014 2423 2429
48. RC Bast, JT Thigpen, SG Arbuck, K Basen-Engquist, LB Burke, R Freedman et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop Gynecol Oncol 107 2007 173 176
49. E Amir, B Seruga, R Kwong, IF Tannock, A Ocaña Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? Eur J Cancer 48 2012 385 388
50. N Methy, L Bedenne, F Bonnetain Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists BMC Cancer 10 2010 277
51. C Feig, A Gopinathan, A Neesse, DS Chan, N Cook, DA Tuveson The pancreas cancer microenvironment Clin Cancer Res 18 2012 4266 4276
52. TM Bauer, BF El-Rayes, X Li, N Hammad, PA Philip, AF Shields et al. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials Cancer 119 2013 285 292
53. W Greenhalf, P Ghaneh, JP Neoptolemos, DH Palmer, TF Cox, RF Lamb et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial J Natl Cancer Inst 106 2014 djt347